Clinical Trial Update: Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effect of bendamustine in combination with rituximab on QT interval in patients with advanced indolent non-Hodgkin's lymphoma or ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)

Snippet

Sponsor: Cephalon | Conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2014-04-04